Work at Jnana Therapeutics Inc. has led to the identification of sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism spectrum disorders, among others.

Protein arginine N-methyltransferase 5 (PRMT5) inhibitors have been disclosed in an Abbisko Therapeutics Co. Ltd. patent and described as potentially useful for the treatment of cancer.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described new 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has patented proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety through a linker.

Tibet Haisco Pharmaceutical Co. Ltd. has prepared new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to androgen receptor variant 7 (AR-v7)-targeting moiety.

Work at Nextgen Bioscience Co. Ltd. has led to the development of purine derivatives acting as hypoxia-inducible factor 1α (HIF-1α) inhibitors.

AC Immune SA has identified pyrrolotriazine and imidazotriazine derivatives acting as NLRP3 inflammasome inhibitors.

A Biogen Inc. patent describes new non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia, inflammatory disorders and autoimmune diseases.

Humanwell Healthcare (Group) Co. Ltd. has described heterocyclic fused benzene ring compounds acting as dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) inhibitors.

Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have prepared and tested new protein cereblon (CRBN) ligands expected to be useful for the treatment of cancer and inflammatory disorders.